Background

The cross-sectional observational International ChoLesterol management Practice Study study assessed achievement of European Society of Cardiology/European Atherosclerosis Society low-density lipoprotein cholesterol (LDL-C) targets in patients outside Western Europe.

Objective

The aim of the study was to assess LDL-C goal achievement in International ChoLesterol management Practice Study participants with familial hypercholesterolemia (FH).

Methods

A total of 334 patients (aged ≥18 years) with definite or probable FH (Dutch Lipid Clinic Network score ≥6; 43.1% genetically confirmed) who had been receiving stable lipid-modifying therapy (LMT) for ≥3 months were enrolled.

Results

The mean ± standard deviation age of the patients was 58.5 ± 13.1 years, 49.1% were male, and 48.2% had coronary artery disease. Most were receiving statin (∼99%). Of these, 57.6% were on high-intensity statin therapy, 49.1% on the highest dose available, and 13.0% used a statin together with a cholesterol absorption inhibitor (CAI). Mean ± standard deviation LDL-C level was 5.6 ± 3.0 mmol/L before LMT and 3.3 ± 2.0 mmol/L at enrollment. Overall, 32.0% of patients achieved their LDL-C target. Target achievement rates were 36.6% for patients with coronary artery disease, and 27.5% for those without, and 27.9%, 28.0%, and 37.5% for patients treated with a statin plus CAI, highest-dose statin (no CAI), and lower-dose statin (no CAI), respectively.

Conclusions

LDL-C target achievement rates were low in patients with FH, even in those receiving intensive LMT. Factors that are likely to have contributed to the low LDL-C target achievement rates include high baseline LDL-C, inadequate statin dosages, and low use of CAI. Many patients would have been eligible for proprotein convertase subtilisin/kexin type 9 inhibitor therapy.

中文翻译：

---

西欧以外国家/地区家族性高胆固醇血症患者的低密度脂蛋白胆固醇目标实现：《国际胆固醇管理实践研究》。

背景

横断面观察性国际ChoLesterol管理实践研究研究评估了欧洲心脏病学会/欧洲动脉粥样硬化学会低密度脂蛋白胆固醇（LDL-C）指标在西欧以外地区患者中取得的成就。

客观的

该研究的目的是评估家族性高胆固醇血症（FH）的国际胆固醇管理实践研究参与者中的LDL-C目标达成情况。

方法

总共纳入了334例接受稳定调脂治疗（LMT）≥3个月的FH（荷兰血脂临床网络评分≥6；经遗传学证实为43.1％）的患者（年龄≥18岁）。

结果

患者的平均±标准差年龄为58.5±13.1岁，男性为49.1％，冠心病为48.2％。大多数接受他汀类药物（约99％）。其中，高强度他汀类药物治疗占57.6％，最大剂量使用49.1％，而他汀类药物与胆固醇吸收抑制剂（CAI）一起使用占13.0％。LMT前的平均±标准偏差LDL-C水平为5.6±3.0 mmol / L，入学时为3.3±2.0 mmol / L。总体而言，32.0％的患者达到了他们的LDL-C目标。他汀类药物加CAI，最高剂量他汀类药物（不使用CAI）治疗的患者的目标完成率分别为：冠心病患者为36.6％，无冠心病患者为27.5％，27.9％，28.0％和37.5％。 -剂量他汀类药物（无CAI）。

结论

FH患者的LDL-C目标达成率很低，即使接受强化LMT的患者也是如此。可能导致低LDL-C目标达成率低的因素包括基线LDL-C高，他汀类药物剂量不足和CAI使用率低。许多患者将有资格接受前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型抑制剂治疗。